María Pascual. VP of Regulatory Affairs and Corporate QA
Address: Marconi, 1. Parque Tecnológico de Madrid
City: 28760 Tres Cantos
Province: Madrid
Phone: 34 91 804 92 64
Fax: 34 91 804 92 63
Mission and Objectives
TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with one marketed product, ChondroCelect, and a strong clinical stage pipeline of adult stem cell programs. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain) and Sittard-Geleen (the Netherlands).
Products/Services, Areas of interest for future collaborations/Alliances
The company’s lead product, ChondroCelect, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated: Cx601, Phase III clinical trial to treat complex perianal fistula in patients with Crohn’s, a Phase IIa trial in rheumatoid arthritis ongoing, and a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders.

Developed by Web4Bio